Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors

R. L. Oostendorp, J. Loftiss, Sanjay Goel, D. A. Smith, M. M. Dar, P. O. Witteveen, R. B. Cohen, L. D. Lewis, S. Kurian, A. Patnaik, H. Rosing, J. H. Beijnen, E. E. Voest, H. Burris, J. H M Schellens

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: The aims of this study were to investigate the bioequivalence of a new oral topotecan formulation (i.e., proposed commercial formulation) relative to the current oral formulation (formulation used in previous clinical trials), the effect of food on the absorption and disposition of the new oral topotecan and its safety and tolerability in patients with advanced solid tumors. Patients and methods: This was a multi-center, pharmacological Phase I, multiple-dose, randomized, open-label, cross-over bioequivalence study. In the bioequivalence part, 85 patients were randomized to receive either a 4 mg (4 × 1 mg) dose of the new or current formulation on Days 1 or 8. In the food-effect part, 23 patients received a 4 mg (4 × 1 mg) dose of the new formulation in a fasted and fed state. Total topotecan and topotecan lactone were determined and pharmacokinetic data were analyzed by non-compartmental method. Results: Bioequivalence was demonstrated as the 90% confidence intervals of the ratio of the new to current formulation for both the area under the plasma concentration-time curve (AUC) and the maximal drug concentration (Cmax) for topotecan lactone were contained within the 0.8 - 1.25 boundary. The AUC and Cmax were similar in the fed and fasted state whilst food delayed the tmax for topotecan lactone and total topotecan. Safety data were collected on all subjects enrolled (n = 108) and were consistent with observations from previous studies of oral topotecan. All subjects experienced at least one adverse event, the majority of which were graded as mild to moderate in severity. Conclusion: The new oral topotecan formulation demonstrated bioequivalence to the current formulation and demonstrated it can be administered to patients with solid tumors in the fed or fasted state with similar systematic exposure.

Original languageEnglish (US)
Pages (from-to)195-206
Number of pages12
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume47
Issue number3
StatePublished - 2009

Fingerprint

Topotecan
Therapeutic Equivalency
Neoplasms
Lactones
Food
Area Under Curve
Safety
Cross-Over Studies
Pharmacokinetics
Clinical Trials
Pharmacology
Confidence Intervals

Keywords

  • Bioequivalence
  • Food-effect
  • Oral formulation
  • Topotecan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. / Oostendorp, R. L.; Loftiss, J.; Goel, Sanjay; Smith, D. A.; Dar, M. M.; Witteveen, P. O.; Cohen, R. B.; Lewis, L. D.; Kurian, S.; Patnaik, A.; Rosing, H.; Beijnen, J. H.; Voest, E. E.; Burris, H.; Schellens, J. H M.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 47, No. 3, 2009, p. 195-206.

Research output: Contribution to journalArticle

Oostendorp, RL, Loftiss, J, Goel, S, Smith, DA, Dar, MM, Witteveen, PO, Cohen, RB, Lewis, LD, Kurian, S, Patnaik, A, Rosing, H, Beijnen, JH, Voest, EE, Burris, H & Schellens, JHM 2009, 'Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors', International Journal of Clinical Pharmacology and Therapeutics, vol. 47, no. 3, pp. 195-206.
Oostendorp, R. L. ; Loftiss, J. ; Goel, Sanjay ; Smith, D. A. ; Dar, M. M. ; Witteveen, P. O. ; Cohen, R. B. ; Lewis, L. D. ; Kurian, S. ; Patnaik, A. ; Rosing, H. ; Beijnen, J. H. ; Voest, E. E. ; Burris, H. ; Schellens, J. H M. / Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. In: International Journal of Clinical Pharmacology and Therapeutics. 2009 ; Vol. 47, No. 3. pp. 195-206.
@article{38ea046aa631480dabc6bf6b373ddc5c,
title = "Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors",
abstract = "Objective: The aims of this study were to investigate the bioequivalence of a new oral topotecan formulation (i.e., proposed commercial formulation) relative to the current oral formulation (formulation used in previous clinical trials), the effect of food on the absorption and disposition of the new oral topotecan and its safety and tolerability in patients with advanced solid tumors. Patients and methods: This was a multi-center, pharmacological Phase I, multiple-dose, randomized, open-label, cross-over bioequivalence study. In the bioequivalence part, 85 patients were randomized to receive either a 4 mg (4 × 1 mg) dose of the new or current formulation on Days 1 or 8. In the food-effect part, 23 patients received a 4 mg (4 × 1 mg) dose of the new formulation in a fasted and fed state. Total topotecan and topotecan lactone were determined and pharmacokinetic data were analyzed by non-compartmental method. Results: Bioequivalence was demonstrated as the 90{\%} confidence intervals of the ratio of the new to current formulation for both the area under the plasma concentration-time curve (AUC) and the maximal drug concentration (Cmax) for topotecan lactone were contained within the 0.8 - 1.25 boundary. The AUC and Cmax were similar in the fed and fasted state whilst food delayed the tmax for topotecan lactone and total topotecan. Safety data were collected on all subjects enrolled (n = 108) and were consistent with observations from previous studies of oral topotecan. All subjects experienced at least one adverse event, the majority of which were graded as mild to moderate in severity. Conclusion: The new oral topotecan formulation demonstrated bioequivalence to the current formulation and demonstrated it can be administered to patients with solid tumors in the fed or fasted state with similar systematic exposure.",
keywords = "Bioequivalence, Food-effect, Oral formulation, Topotecan",
author = "Oostendorp, {R. L.} and J. Loftiss and Sanjay Goel and Smith, {D. A.} and Dar, {M. M.} and Witteveen, {P. O.} and Cohen, {R. B.} and Lewis, {L. D.} and S. Kurian and A. Patnaik and H. Rosing and Beijnen, {J. H.} and Voest, {E. E.} and H. Burris and Schellens, {J. H M}",
year = "2009",
language = "English (US)",
volume = "47",
pages = "195--206",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "3",

}

TY - JOUR

T1 - Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors

AU - Oostendorp, R. L.

AU - Loftiss, J.

AU - Goel, Sanjay

AU - Smith, D. A.

AU - Dar, M. M.

AU - Witteveen, P. O.

AU - Cohen, R. B.

AU - Lewis, L. D.

AU - Kurian, S.

AU - Patnaik, A.

AU - Rosing, H.

AU - Beijnen, J. H.

AU - Voest, E. E.

AU - Burris, H.

AU - Schellens, J. H M

PY - 2009

Y1 - 2009

N2 - Objective: The aims of this study were to investigate the bioequivalence of a new oral topotecan formulation (i.e., proposed commercial formulation) relative to the current oral formulation (formulation used in previous clinical trials), the effect of food on the absorption and disposition of the new oral topotecan and its safety and tolerability in patients with advanced solid tumors. Patients and methods: This was a multi-center, pharmacological Phase I, multiple-dose, randomized, open-label, cross-over bioequivalence study. In the bioequivalence part, 85 patients were randomized to receive either a 4 mg (4 × 1 mg) dose of the new or current formulation on Days 1 or 8. In the food-effect part, 23 patients received a 4 mg (4 × 1 mg) dose of the new formulation in a fasted and fed state. Total topotecan and topotecan lactone were determined and pharmacokinetic data were analyzed by non-compartmental method. Results: Bioequivalence was demonstrated as the 90% confidence intervals of the ratio of the new to current formulation for both the area under the plasma concentration-time curve (AUC) and the maximal drug concentration (Cmax) for topotecan lactone were contained within the 0.8 - 1.25 boundary. The AUC and Cmax were similar in the fed and fasted state whilst food delayed the tmax for topotecan lactone and total topotecan. Safety data were collected on all subjects enrolled (n = 108) and were consistent with observations from previous studies of oral topotecan. All subjects experienced at least one adverse event, the majority of which were graded as mild to moderate in severity. Conclusion: The new oral topotecan formulation demonstrated bioequivalence to the current formulation and demonstrated it can be administered to patients with solid tumors in the fed or fasted state with similar systematic exposure.

AB - Objective: The aims of this study were to investigate the bioequivalence of a new oral topotecan formulation (i.e., proposed commercial formulation) relative to the current oral formulation (formulation used in previous clinical trials), the effect of food on the absorption and disposition of the new oral topotecan and its safety and tolerability in patients with advanced solid tumors. Patients and methods: This was a multi-center, pharmacological Phase I, multiple-dose, randomized, open-label, cross-over bioequivalence study. In the bioequivalence part, 85 patients were randomized to receive either a 4 mg (4 × 1 mg) dose of the new or current formulation on Days 1 or 8. In the food-effect part, 23 patients received a 4 mg (4 × 1 mg) dose of the new formulation in a fasted and fed state. Total topotecan and topotecan lactone were determined and pharmacokinetic data were analyzed by non-compartmental method. Results: Bioequivalence was demonstrated as the 90% confidence intervals of the ratio of the new to current formulation for both the area under the plasma concentration-time curve (AUC) and the maximal drug concentration (Cmax) for topotecan lactone were contained within the 0.8 - 1.25 boundary. The AUC and Cmax were similar in the fed and fasted state whilst food delayed the tmax for topotecan lactone and total topotecan. Safety data were collected on all subjects enrolled (n = 108) and were consistent with observations from previous studies of oral topotecan. All subjects experienced at least one adverse event, the majority of which were graded as mild to moderate in severity. Conclusion: The new oral topotecan formulation demonstrated bioequivalence to the current formulation and demonstrated it can be administered to patients with solid tumors in the fed or fasted state with similar systematic exposure.

KW - Bioequivalence

KW - Food-effect

KW - Oral formulation

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=65549170681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549170681&partnerID=8YFLogxK

M3 - Article

C2 - 19281729

AN - SCOPUS:65549170681

VL - 47

SP - 195

EP - 206

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 3

ER -